Kari J Furtek1, David W Kubiak2, Megan Barra2, Christy A Varughese3, Cameron D Ashbaugh4, Sophia Koo4. 1. School of Pharmacy, Northeastern University, Boston, MA, USA Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA kfurtek@gmail.com. 2. Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA. 3. Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA. 4. Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA Harvard Medical School, Boston, MA, USA.
Abstract
OBJECTIVES: We sought to determine the rate of incident neutropenia and identify potential clinical factors associated with incident neutropenia among patients treated with long courses of ceftaroline. METHODS: We retrospectively identified adult patients who received ceftaroline for ≥7 days consecutively at two large academic medical centres in Boston, USA between November 2010 and March 2015. Clinical characteristics (age, gender, medication allergies, baseline renal function, duration of ceftaroline exposure, total daily ceftaroline dose, body mass-adjusted ceftaroline dose and development of rash and neutropenia) were recorded and the rate of incident neutropenia was calculated. The Naranjo probability scale was used to assess whether ceftaroline exposure was associated with neutropenia. We assessed whether clinical factors were associated with neutropenia. RESULTS: The overall rate of incident neutropenia was 10%-14% with ≥2 weeks and 21% with ≥3 weeks of ceftaroline exposure. The median duration of ceftaroline exposure [26 days (IQR 22-44; range 13-68) in patients who developed neutropenia and 15 days (IQR 9-29; range 7-64) in patients without neutropenia] was associated with incident neutropenia (P = 0.048). The median total number of ceftaroline doses received [63 (IQR 44-126; range 36-198) by neutropenic patients and 32 (IQR 22-63; range 14-180) by non-neutropenic patients] was also associated with incident neutropenia (P = 0.023). CONCLUSIONS: The overall rate of neutropenia was high and associated with duration of ceftaroline exposure and total number of doses received. Close laboratory monitoring is warranted with long-term ceftaroline use.
OBJECTIVES: We sought to determine the rate of incident neutropenia and identify potential clinical factors associated with incident neutropenia among patients treated with long courses of ceftaroline. METHODS: We retrospectively identified adult patients who received ceftaroline for ≥7 days consecutively at two large academic medical centres in Boston, USA between November 2010 and March 2015. Clinical characteristics (age, gender, medication allergies, baseline renal function, duration of ceftaroline exposure, total daily ceftaroline dose, body mass-adjusted ceftaroline dose and development of rash and neutropenia) were recorded and the rate of incident neutropenia was calculated. The Naranjo probability scale was used to assess whether ceftaroline exposure was associated with neutropenia. We assessed whether clinical factors were associated with neutropenia. RESULTS: The overall rate of incident neutropenia was 10%-14% with ≥2 weeks and 21% with ≥3 weeks of ceftaroline exposure. The median duration of ceftaroline exposure [26 days (IQR 22-44; range 13-68) in patients who developed neutropenia and 15 days (IQR 9-29; range 7-64) in patients without neutropenia] was associated with incident neutropenia (P = 0.048). The median total number of ceftaroline doses received [63 (IQR 44-126; range 36-198) by neutropenicpatients and 32 (IQR 22-63; range 14-180) by non-neutropenicpatients] was also associated with incident neutropenia (P = 0.023). CONCLUSIONS: The overall rate of neutropenia was high and associated with duration of ceftaroline exposure and total number of doses received. Close laboratory monitoring is warranted with long-term ceftaroline use.
Authors: Tony T Ho; Jose Cadena; Lindsey M Childs; Miguel Gonzalez-Velez; James S Lewis Journal: J Antimicrob Chemother Date: 2012-02-06 Impact factor: 5.790
Authors: C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt Journal: Clin Pharmacol Ther Date: 1981-08 Impact factor: 6.875
Authors: Rupali Jain; Jeannie D Chan; Lisa Rogers; Timothy H Dellit; John B Lynch; Paul S Pottinger Journal: Pharmacotherapy Date: 2014-05-07 Impact factor: 4.705
Authors: Rachel S Britt; Kirk E Evoy; Grace C Lee; Kelly R Reveles; Kimberly M Sorensen; Xavier Jones; Mary Bollinger; Christopher R Frei Journal: Drugs Date: 2017-08 Impact factor: 9.546
Authors: T D Trinh; S C J Jorgensen; E J Zasowski; K C Claeys; A M Lagnf; S J Estrada; D J Delaportes; V Huang; K P Klinker; K S Kaye; S L Davis; M J Rybak Journal: Antimicrob Agents Chemother Date: 2019-10-22 Impact factor: 5.191
Authors: Kap Sum Foong; Kevin Hsueh; Thomas C Bailey; Lan Luong; Ayesha Iqbal; Christine Hoehner; Lee Connor; Ed Casabar; Michael Lane; Yvonne Burnett; David Ritchie; Tamara Krekel; Helen Newland; Lori Weilmuenster; Brett Heuring; Michael J Durkin; Yasir Hamad Journal: Clin Infect Dis Date: 2019-07-18 Impact factor: 9.079
Authors: Despoina Koulenti; Elena Xu; Isaac Yin Sum Mok; Andrew Song; Drosos E Karageorgopoulos; Apostolos Armaganidis; Jeffrey Lipman; Sotirios Tsiodras Journal: Microorganisms Date: 2019-08-18